MX2023002191A - Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca. - Google Patents
Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca.Info
- Publication number
- MX2023002191A MX2023002191A MX2023002191A MX2023002191A MX2023002191A MX 2023002191 A MX2023002191 A MX 2023002191A MX 2023002191 A MX2023002191 A MX 2023002191A MX 2023002191 A MX2023002191 A MX 2023002191A MX 2023002191 A MX2023002191 A MX 2023002191A
- Authority
- MX
- Mexico
- Prior art keywords
- hla
- antibodies
- mass
- binding activity
- treatment
- Prior art date
Links
- 208000015943 Coeliac disease Diseases 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 108010068370 Glutens Proteins 0.000 abstract 4
- 230000027455 binding Effects 0.000 abstract 4
- 235000021312 gluten Nutrition 0.000 abstract 4
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 3
- 229930195729 fatty acid Natural products 0.000 abstract 3
- 239000000194 fatty acid Substances 0.000 abstract 3
- 150000004665 fatty acids Chemical class 0.000 abstract 3
- 230000006044 T cell activation Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 235000021355 Stearic acid Nutrition 0.000 abstract 1
- 239000002280 amphoteric surfactant Substances 0.000 abstract 1
- 239000012459 cleaning agent Substances 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000008117 stearic acid Substances 0.000 abstract 1
- 150000005846 sugar alcohols Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Botany (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a los anticuerpos anti-HLA-DQ2.5 y su uso para el tratamiento de la enfermedad celíaca. La presente invención proporciona anticuerpos anti-HLA-DQ2.5 que han sido modificados. Los anticuerpos anti-HLA-DQ2.5 de la invención tienen una actividad de unión a los complejos formados por HLA-DQ2.5 y un péptido de gluten, pero no tienen, sustancialmente, una actividad de unión a los complejos formados por HLA-DQ2.5 y un péptido irrelevante. Además, los anticuerpos de la invención demuestran tener efectos inhibidores sobre la activación de la célula T mediante péptidos de gluten.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020157873 | 2020-09-18 | ||
| PCT/JP2021/034240 WO2022059766A1 (en) | 2020-09-18 | 2021-09-17 | Anti-hla-dq2.5 antibody and its use for the treatment of celiac disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002191A true MX2023002191A (es) | 2023-03-03 |
Family
ID=80739984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002191A MX2023002191A (es) | 2020-09-18 | 2021-09-17 | Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11739153B2 (es) |
| EP (1) | EP4214236A1 (es) |
| JP (2) | JP7147030B2 (es) |
| KR (2) | KR20230116942A (es) |
| CN (3) | CN117801114A (es) |
| AR (1) | AR123537A1 (es) |
| AU (1) | AU2021343008A1 (es) |
| CA (1) | CA3192661A1 (es) |
| CL (1) | CL2023000765A1 (es) |
| CO (1) | CO2023003681A2 (es) |
| CR (1) | CR20230166A (es) |
| IL (1) | IL301326A (es) |
| MX (1) | MX2023002191A (es) |
| PE (1) | PE20231208A1 (es) |
| TW (2) | TW202402804A (es) |
| WO (1) | WO2022059766A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20231208A1 (es) | 2020-09-18 | 2023-08-17 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca |
| CA3232707A1 (en) * | 2021-10-08 | 2023-04-13 | Kengo ARAI | Drug formulation of anti-hla-dq2.5 antibody |
| IL311956A (en) * | 2021-10-08 | 2024-06-01 | Chugai Pharmaceutical Co Ltd | Method for preparing a prefilled syringe formulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| IL158342A0 (en) | 2001-04-12 | 2004-05-12 | Academisch Ziekenhuis Leiden | Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides |
| SG10201402265YA (en) | 2008-02-07 | 2014-08-28 | Amgen Inc | Stabilized protein compositions |
| AU2013204429B9 (en) | 2008-11-30 | 2017-01-05 | Immusant, Inc. | Compositions and methods for treatment of celiac disease |
| EP2437780B1 (en) | 2009-06-04 | 2016-03-23 | The Regents of the University of Colorado | Therapeutic compositions and methods for the prevention of autoimmune diseases |
| CN103209709A (zh) | 2010-08-05 | 2013-07-17 | 弗·哈夫曼-拉罗切有限公司 | 抗mhc抗体抗病毒性细胞因子融合蛋白 |
| KR102168733B1 (ko) * | 2011-10-31 | 2020-10-23 | 추가이 세이야쿠 가부시키가이샤 | 중쇄와 경쇄의 회합이 제어된 항원 결합 분자 |
| WO2016202805A2 (en) | 2015-06-15 | 2016-12-22 | Consejo Superior De Investigaciones Científicas (Csic) | Targeting of prolamin by rnai in bread wheat |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| EP3585818A4 (en) * | 2017-02-27 | 2020-12-23 | Chugai Seiyaku Kabushiki Kaisha | ANTI-HLA-DQ2.5 / 8 ANTIBODIES AND ITS USE FOR THE TREATMENT OF C LIATIC DISEASE |
| JP7299212B2 (ja) * | 2017-10-03 | 2023-06-27 | 中外製薬株式会社 | 抗ｈｌａ－ｄｑ２．５抗体 |
| GB201802338D0 (en) * | 2018-02-13 | 2018-03-28 | Univ Oslo | Antigen binding proteins |
| WO2020204054A1 (en) | 2019-04-01 | 2020-10-08 | Chugai Seiyaku Kabushiki Kaisha | Anti-hla-dq2.5 antibody |
| PE20231208A1 (es) | 2020-09-18 | 2023-08-17 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca |
-
2021
- 2021-09-17 PE PE2023001173A patent/PE20231208A1/es unknown
- 2021-09-17 KR KR1020237024631A patent/KR20230116942A/ko active Application Filing
- 2021-09-17 IL IL301326A patent/IL301326A/en unknown
- 2021-09-17 AU AU2021343008A patent/AU2021343008A1/en active Pending
- 2021-09-17 JP JP2021151709A patent/JP7147030B2/ja active Active
- 2021-09-17 EP EP21869449.5A patent/EP4214236A1/en active Pending
- 2021-09-17 CA CA3192661A patent/CA3192661A1/en active Pending
- 2021-09-17 CN CN202311813323.8A patent/CN117801114A/zh active Pending
- 2021-09-17 KR KR1020217042982A patent/KR102559128B1/ko active IP Right Grant
- 2021-09-17 WO PCT/JP2021/034240 patent/WO2022059766A1/en active Application Filing
- 2021-09-17 MX MX2023002191A patent/MX2023002191A/es unknown
- 2021-09-17 CR CR20230166A patent/CR20230166A/es unknown
- 2021-09-17 TW TW112137009A patent/TW202402804A/zh unknown
- 2021-09-17 CN CN202180061976.8A patent/CN116096757B/zh active Active
- 2021-09-17 US US17/477,651 patent/US11739153B2/en active Active
- 2021-09-17 TW TW110134821A patent/TWI820484B/zh active
- 2021-09-17 AR ARP210102585A patent/AR123537A1/es unknown
- 2021-09-17 CN CN202311818773.6A patent/CN117801115A/zh active Pending
-
2022
- 2022-09-02 JP JP2022139889A patent/JP2022172276A/ja active Pending
-
2023
- 2023-03-16 CL CL2023000765A patent/CL2023000765A1/es unknown
- 2023-03-23 CO CONC2023/0003681A patent/CO2023003681A2/es unknown
- 2023-07-05 US US18/346,975 patent/US20230357408A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022051553A (ja) | 2022-03-31 |
| US20230357408A1 (en) | 2023-11-09 |
| CO2023003681A2 (es) | 2023-04-05 |
| CN117801115A (zh) | 2024-04-02 |
| JP2022172276A (ja) | 2022-11-15 |
| US11739153B2 (en) | 2023-08-29 |
| TW202402804A (zh) | 2024-01-16 |
| CN116096757B (zh) | 2024-01-12 |
| CR20230166A (es) | 2023-05-31 |
| CA3192661A1 (en) | 2022-03-24 |
| PE20231208A1 (es) | 2023-08-17 |
| EP4214236A1 (en) | 2023-07-26 |
| AR123537A1 (es) | 2022-12-14 |
| TW202229345A (zh) | 2022-08-01 |
| WO2022059766A1 (en) | 2022-03-24 |
| CN117801114A (zh) | 2024-04-02 |
| TWI820484B (zh) | 2023-11-01 |
| JP7147030B2 (ja) | 2022-10-04 |
| AU2021343008A1 (en) | 2023-06-01 |
| KR102559128B1 (ko) | 2023-07-24 |
| KR20230116942A (ko) | 2023-08-04 |
| CN116096757A (zh) | 2023-05-09 |
| CL2023000765A1 (es) | 2023-11-03 |
| IL301326A (en) | 2023-05-01 |
| KR20220153469A (ko) | 2022-11-18 |
| US20220089743A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002191A (es) | Anticuerpo anti antigenos de leucocitos humanos (hla) isoforma dq2.5 y su uso para el tratamiento de la enfermedad celiaca. | |
| Tan et al. | Venom proteomics and antivenom neutralization for the Chinese eastern Russell’s viper, Daboia siamensis from Guangxi and Taiwan | |
| PH12019502356A1 (en) | Trem2 antigen binding proteins and uses thereof | |
| MX2023001726A (es) | Anticuerpos anti-c5 y usos de los mismos. | |
| NZ599035A (en) | Antibodies to ox-2/cd200 and uses thereof | |
| EP2062047B1 (fr) | Methode d'investigation de la reponse a un traitement par un anticorps monoclonal | |
| Eller et al. | Expansion of inefficient HIV-specific CD8 T cells during acute infection | |
| MX2022008582A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| WO2021163369A3 (en) | Methods of treating age-related and inflammatory diseases | |
| AR021296A1 (es) | Un anticuerpo humanizado especifico para 4-1bb humano y composiciones farmaceuticas que lo comprenden | |
| GEP20105059B (en) | Anti-cd154 antibodies | |
| DE60334141D1 (de) | VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE | |
| JP2011511780A5 (es) | ||
| PH12021550255A1 (en) | Anti-npr1 antibodies and uses thereof | |
| Paiva et al. | Combined venom gland cDNA sequencing and venomics of the New Guinea small-eyed snake, Micropechis ikaheka | |
| FR3078535B1 (fr) | Composition vaccinale anti-pd-l1 | |
| Lee et al. | Characterization of β-secretase inhibitory peptide purified from skate skin protein hydrolysate | |
| MX2023002901A (es) | Anticuerpos que se unen a la proteína auxiliar del receptor de interleucina-1 (il1rap) y usos de estos. | |
| Ilves et al. | Decrease in chymase activity is associated with increase in IL-6 expression in mast cells in atopic dermatitis | |
| MX2022000484A (es) | Anticuerpos contra bssl novedosos. | |
| Carlier et al. | Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors | |
| Ancuta et al. | Involvement of the membrane form of tumour necrosis factor‐&agr; in lipopolysaccharide‐induced priming of mouse peritoneal macrophages for enhanced nitric oxide response to lipopolysaccharide | |
| Shi et al. | Characterization of Fc gamma receptor IIb expression within abdominal aortic aneurysm | |
| DE60127102D1 (de) | Regulation des menschliches lipoxin a4 rezeptor-ähnliches protein | |
| MX2023006869A (es) | Proteinas de union condicionalmente biespecificas. |